Examiner: WILLIS, DOUGLAS M

Tech Center 1600 • Art Units: 1624 1691

This examiner grants 82% of resolved cases

Performance Statistics

82.4%

Allow Rate

+22.4% vs TC avg

1,838

Total Applications

+19.5%

Interview Lift

685

Avg Prosecution Days

Based on 1802 resolved cases, 2023–2026

0.9%

§101 Eligibility

17.8%

§102 Novelty

8.9%

§103 Obviousness

52.8%

§112 Clarity

App #	Title	Status	Assignee
18315472	N-[2-({4-[3-(ANILINO)-4-OXO-4,5,6,7-TETRAHYDRO-1H-PYRROLO[3,2-C]PYRIDIN-2-YL]PYRIDIN-3-YL)OXY)ETHYL]PROP-2-ENAMIDE DERIVATIVES AND SIMILAR COMPOUNDS AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER	Final Rejection	Dana-Farber Cancer Institute, Inc.
18710429	INHIBITORS OF THE ONCOGENIC SHP2 PHOSPHATASE AND USES THEREOF	Non-Final OA	Sanford Burnham Prebys Medical Discovery Institute

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.